Enhancing the Response Rate to Recombinant Uricases in Patients with Gout Naomi SchlesingerLissa Padnick-SilverBrian LaMoreaux Leading Article Open access 22 March 2022 Pages: 95 - 103
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic Morgan E. RookAmber L. Southwell Leading Article 07 March 2022 Pages: 105 - 119
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy? Natalie C. WardDick C. ChanGerald F. Watts Review Article Open access 14 March 2022 Pages: 121 - 135
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data Maxime BoussageonAurélie SwalduzOlivier Bylicki Review Article 11 February 2022 Pages: 137 - 151
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy Nicholas P. TscherniaJames L. Gulley Review Article Open access 30 March 2022 Pages: 153 - 180
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics Ruipeng MuJiaqi YuanAnton I. Rosenbaum Review Article Open access 01 April 2022 Pages: 181 - 196
Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases Mehak BassiSiddharth Singh Review Article 23 March 2022 Pages: 197 - 203
Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study Wan-Ju Annabelle LeeShih-Chieh ShaoEdward Chia-Cheng Lai Original Research Article 01 March 2022 Pages: 205 - 216
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe Teresa Barcina LacostaArnold G. VultoSteven Simoens Original Research Article Open access 18 March 2022 Pages: 217 - 229
